- REPORT SUMMARY
- TABLE OF CONTENTS
-
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies market report explains the definition, types, applications, major countries, and major players of the Biosimilar Monoclonal Antibodies market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Cadila Healthcare
Hisun Pharma
Celgen Biopharma
Pfizer (Hospira)
Novartis (Sandoz)
Dr Reddy’s
Celltrion
Torrent Pharmaceuticals
3SBIO
By Type:
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
By End-User:
Oncology
Autoimmune Disease
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Biosimilar Monoclonal Antibodies Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Biosimilar Monoclonal Antibodies Outlook to 2028- Original Forecasts
-
2.2 Biosimilar Monoclonal Antibodies Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Biosimilar Monoclonal Antibodies Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Biosimilar Monoclonal Antibodies Market- Recent Developments
-
6.1 Biosimilar Monoclonal Antibodies Market News and Developments
-
6.2 Biosimilar Monoclonal Antibodies Market Deals Landscape
7 Biosimilar Monoclonal Antibodies Raw Materials and Cost Structure Analysis
-
7.1 Biosimilar Monoclonal Antibodies Key Raw Materials
-
7.2 Biosimilar Monoclonal Antibodies Price Trend of Key Raw Materials
-
7.3 Biosimilar Monoclonal Antibodies Key Suppliers of Raw Materials
-
7.4 Biosimilar Monoclonal Antibodies Market Concentration Rate of Raw Materials
-
7.5 Biosimilar Monoclonal Antibodies Cost Structure Analysis
-
7.5.1 Biosimilar Monoclonal Antibodies Raw Materials Analysis
-
7.5.2 Biosimilar Monoclonal Antibodies Labor Cost Analysis
-
7.5.3 Biosimilar Monoclonal Antibodies Manufacturing Expenses Analysis
8 Global Biosimilar Monoclonal Antibodies Import and Export Analysis (Top 10 Countries)
-
8.1 Global Biosimilar Monoclonal Antibodies Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Biosimilar Monoclonal Antibodies Export by Region (Top 10 Countries) (2017-2028)
9 Global Biosimilar Monoclonal Antibodies Market Outlook by Types and Applications to 2022
-
9.1 Global Biosimilar Monoclonal Antibodies Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Infliximab Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Rituximab Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Trastuzumab Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Adalimumab Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Biosimilar Monoclonal Antibodies Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Autoimmune Disease Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Biosimilar Monoclonal Antibodies Market Analysis and Outlook till 2022
-
10.1 Global Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.2.2 Canada Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.2.3 Mexico Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.2 UK Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.3 Spain Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.4 Belgium Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.5 France Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.6 Italy Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.7 Denmark Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.8 Finland Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.9 Norway Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.10 Sweden Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.11 Poland Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.12 Russia Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.3.13 Turkey Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.2 Japan Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.3 India Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.4 South Korea Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.5 Pakistan Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.6 Bangladesh Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.7 Indonesia Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.8 Thailand Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.9 Singapore Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.10 Malaysia Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.11 Philippines Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.4.12 Vietnam Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.2 Colombia Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.3 Chile Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.4 Argentina Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.5 Venezuela Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.6 Peru Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.7 Puerto Rico Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.5.8 Ecuador Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.6.2 Kuwait Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.6.3 Oman Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.6.4 Qatar Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.6.5 Saudi Arabia Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.6.6 United Arab Emirates Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.7.2 South Africa Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.7.3 Egypt Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.7.4 Algeria Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Biosimilar Monoclonal Antibodies Consumption (2017-2022)
-
10.8.2 New Zealand Biosimilar Monoclonal Antibodies Consumption (2017-2022)
11 Global Biosimilar Monoclonal Antibodies Competitive Analysis
-
11.1 Cadila Healthcare
-
11.1.1 Cadila Healthcare Company Details
-
11.1.2 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.1.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Hisun Pharma
-
11.2.1 Hisun Pharma Company Details
-
11.2.2 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Hisun Pharma Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.2.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Celgen Biopharma
-
11.3.1 Celgen Biopharma Company Details
-
11.3.2 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.3.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Pfizer (Hospira)
-
11.4.1 Pfizer (Hospira) Company Details
-
11.4.2 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.4.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Novartis (Sandoz)
-
11.5.1 Novartis (Sandoz) Company Details
-
11.5.2 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.5.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Dr Reddy’s
-
11.6.1 Dr Reddy’s Company Details
-
11.6.2 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.6.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Celltrion
-
11.7.1 Celltrion Company Details
-
11.7.2 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Celltrion Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.7.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Torrent Pharmaceuticals
-
11.8.1 Torrent Pharmaceuticals Company Details
-
11.8.2 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.8.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 3SBIO
-
11.9.1 3SBIO Company Details
-
11.9.2 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 3SBIO Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
11.9.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
-
11.9.5 Recent Research and Development Strategies
12 Global Biosimilar Monoclonal Antibodies Market Outlook by Types and Applications to 2028
-
12.1 Global Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Infliximab Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Rituximab Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Trastuzumab Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Autoimmune Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Biosimilar Monoclonal Antibodies Market Analysis and Outlook to 2028
-
13.1 Global Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.2.2 Canada Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.2.3 Mexico Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.2 UK Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.3 Spain Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.4 Belgium Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.5 France Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.6 Italy Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.7 Denmark Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.8 Finland Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.9 Norway Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.10 Sweden Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.11 Poland Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.12 Russia Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.3.13 Turkey Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.2 Japan Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.3 India Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.4 South Korea Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.8 Thailand Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.9 Singapore Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.11 Philippines Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.2 Colombia Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.3 Chile Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.4 Argentina Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.6 Peru Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.6.3 Oman Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.6.4 Qatar Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.7.2 South Africa Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.7.3 Egypt Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.7.4 Algeria Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Biosimilar Monoclonal Antibodies
-
Figure of Biosimilar Monoclonal Antibodies Picture
-
Table Global Biosimilar Monoclonal Antibodies Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Biosimilar Monoclonal Antibodies Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Infliximab Consumption and Growth Rate (2017-2022)
-
Figure Global Rituximab Consumption and Growth Rate (2017-2022)
-
Figure Global Trastuzumab Consumption and Growth Rate (2017-2022)
-
Figure Global Adalimumab Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Oncology Consumption and Growth Rate (2017-2022)
-
Figure Global Autoimmune Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Table North America Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure United States Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Canada Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Mexico Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table Europe Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure Germany Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure UK Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Spain Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Belgium Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure France Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Italy Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Denmark Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Finland Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Norway Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Sweden Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Poland Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Russia Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Turkey Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table APAC Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure China Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Japan Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure India Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure South Korea Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Thailand Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Singapore Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Philippines Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table South America Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure Brazil Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Colombia Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Chile Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Argentina Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Peru Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table GCC Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure Bahrain Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Oman Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Qatar Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table Africa Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure Nigeria Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure South Africa Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Egypt Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Algeria Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table Oceania Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)
-
Figure Australia Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Table Cadila Healthcare Company Details
-
Table Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cadila Healthcare Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Hisun Pharma Company Details
-
Table Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hisun Pharma Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Celgen Biopharma Company Details
-
Table Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgen Biopharma Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Pfizer (Hospira) Company Details
-
Table Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer (Hospira) Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Novartis (Sandoz) Company Details
-
Table Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis (Sandoz) Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Dr Reddy’s Company Details
-
Table Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Reddy’s Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Celltrion Company Details
-
Table Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celltrion Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
-
Table Torrent Pharmaceuticals Company Details
-
Table Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
-
Table 3SBIO Company Details
-
Table 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)
-
Table 3SBIO Biosimilar Monoclonal Antibodies Main Business and Markets Served
-
Table 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
-
Figure Global Infliximab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rituximab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Trastuzumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Autoimmune Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Table North America Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure United States Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure Germany Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure China Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure Brazil Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)
-
Figure Australia Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-